Low Testosterone · 11 min read · Published 2026-05-16
Low Testosterone: HPG Axis, SHBG, and the Evidence for Nutritional Intervention
Testosterone deficiency is frequently mischaracterized as a single-variable problem. In practice, the diagnostic and mechanistic picture spans three interdependent layers: hypothalamic-pituitary-gonadal (HPG) axis signaling fidelity, sex hormone-binding globulin (SHBG) concentration as the primary determinant of bioavailable testosterone, and intratesticular steroidogenic enzyme activity. A total testosterone measurement — the standard clinical readout — captures only a fraction of this picture. SHBG binds testosterone with high affinity (Kd ≈ 1 nM), leaving only 2–3% of circulating testosterone in the free, receptor-accessible fraction. Men with total testosterone in the low-normal range (350–450 ng/dL) and elevated SHBG can be functionally hypogonadal; conversely, men with modestly low total T but suppressed SHBG may be phenotypically eugonadal.
Testosterone secretion follows a hard circadian pattern: peak concentrations at 07:00–09:00 are 20–25% above nadir values at 20:00–22:00, driven by the amplitude of GnRH pulsatility from the suprachiasmatic nucleus. This temporal architecture is clinically and pharmacologically relevant — it defines the intervention window for compounds acting upstream on LH amplitude or downstream on steroidogenesis. The mechanistic literature on nutritional modulators of this axis — particularly zinc, vitamin D3/VDR signaling, and Eurycoma longifolia — is more rigorous than most practitioners acknowledge. This post examines the molecular substrate and the quality of the clinical evidence.
HPG Axis to Testosterone: StAR, CYP11A1, and the Steroidogenic Cascade
Testosterone biosynthesis begins at the inner mitochondrial membrane of Leydig cells. The rate-limiting step is cholesterol transport from the outer to inner mitochondrial membrane, mediated by the Steroidogenic Acute Regulatory (StAR) protein — a 30 kDa phosphoprotein whose expression is acutely upregulated by LH/cAMP signaling within minutes. StAR delivers cholesterol to CYP11A1 (cytochrome P450 side-chain cleavage enzyme), which catalyzes the first committed step: cholesterol → pregnenolone. From pregnenolone, the Δ5 pathway proceeds through 17α-hydroxypregnenolone and DHEA, with CYP17A1 (17α-hydroxylase/17,20-lyase) driving the branch toward androgen precursors. 3β-HSD converts DHEA to androstenedione; 17β-HSD3 reduces androstenedione to testosterone.
This cascade is pulsatile, not tonic — LH is secreted in discrete bursts (approximately every 90 minutes), and Leydig cell cAMP/PKA activation is transient. Chronic LH elevation (as seen in primary hypogonadism) downregulates LH receptors via internalization, a negative feedback that places an upper ceiling on pharmacological LH stimulation. Understanding this ceiling is essential when evaluating compounds that act as LH secretagogues — they are most effective in men with intact but underactivated Leydig cell function, not in those with receptor desensitization from longstanding primary failure.
SHBG Dynamics and Free Testosterone: Why Total T Is an Insufficient Diagnostic
SHBG is a hepatically synthesized glycoprotein that binds testosterone and estradiol with high affinity. Factors that elevate SHBG — aging (each decade adds ~1.2 nmol/L), hyperthyroidism, hepatic inflammation, and certain medications — compress the free testosterone fraction independent of total T. Factors that suppress SHBG — obesity, insulin resistance, elevated DHT, hypothyroidism — can artificially inflate free T relative to total T.
The free androgen index (FAI = total T / SHBG × 100) and directly measured free testosterone by equilibrium dialysis are the preferred metrics for functional androgen status. Calculated free testosterone (Vermeulen equation) correlates reasonably with dialysis methods (r = 0.92) and is more practical clinically. The clinical relevance: in a cohort of 400 men presenting with hypogonadal symptoms, approximately 20–25% will have normal total T but low free T attributable to SHBG elevation. These men are systematically undertreated by symptom-blind total-T thresholds. Compounds that reduce SHBG — notably boron (demonstrated 28% reduction in SHBG after 4 weeks at 10 mg/day in one RCT) and eurycomanone from tongkat ali — act at this layer, improving bioavailable testosterone without directly stimulating steroidogenesis.
Zinc, Vitamin D3/VDR, and Steroidogenic Enzyme Modulation
Zinc occupies a critical position in the steroidogenic pathway through two distinct mechanisms. First, zinc is a cofactor for 5α-reductase, the enzyme that converts testosterone to the more potent androgen DHT; paradoxically, zinc also has inhibitory activity at 5α-reductase at higher concentrations, suggesting a modulatory rather than purely activating role. Second, and more directly, zinc functions as an aromatase (CYP19A1) co-factor — zinc chelation studies demonstrate that aromatase activity is zinc-dependent, and zinc deficiency is associated with increased aromatase activity and elevated estrogen:testosterone ratios. Athletes lose significant zinc through sweat (estimated 0.6–1.0 mg/L), making deficiency common in high-training populations.
Vitamin D3, via its active metabolite 1,25-dihydroxyvitamin D3 (calcitriol), acts through the vitamin D receptor (VDR), a nuclear receptor expressed in Leydig cells. VDR-mediated genomic signaling upregulates StAR transcription and CYP11A1 expression in Leydig cells — a direct steroidogenic effect. A 2024 meta-analysis of 17 RCTs (PMID 39452471) found vitamin D supplementation produced a weighted mean difference of +0.38 nmol/L in total testosterone (95% CI: 0.19–0.57 nmol/L). Effect sizes were largest in men with baseline 25(OH)D below 50 nmol/L, consistent with a deficiency-correction mechanism rather than supraphysiologic pharmacology.
Tongkat Ali: Eurycomanone Mechanism and the 2022 Meta-Analysis
Eurycoma longifolia (tongkat ali) contains quassinoid compounds — most notably eurycomanone — that appear to act at multiple nodes in the HPG axis. Proposed mechanisms include: inhibition of sex hormone-binding globulin binding (reducing SHBG:testosterone affinity), stimulation of LH release from pituitary gonadotrophs (possibly via GnRH receptor sensitization), and direct Leydig cell StAR upregulation in animal models. The SHBG competition mechanism is the best characterized: eurycomanone's steroidal backbone allows it to compete for SHBG binding sites, increasing the free fraction of endogenous testosterone without changing total T output.
The 2022 systematic review and meta-analysis (PMID 36013514) pooled data from RCTs in hypogonadal men using standardized LJ100 extract (200 mg/day) and found a standardized mean difference of 1.35 for testosterone (95% CI: 0.65–2.05) — a large effect size by Cohen's conventions, though heterogeneity was substantial (I² = 78%), reflecting variation in study populations and baseline testosterone levels. Crucially, effect sizes were largest in men with confirmed hypogonadism at baseline; eugonadal men showed attenuated responses, consistent with a ceiling effect in the axis. This population specificity is a key consideration for protocol design — tongkat ali is most likely to produce clinically meaningful improvement in men whose HPG axis is functional but underactivated, not in men with structural Leydig cell failure.
The bottom line
The mechanistic substrate for nutritional modulation of the HPG axis is substantive and underappreciated in clinical practice. Zinc, vitamin D3, and tongkat ali each operate at distinct, non-redundant nodes — steroidogenic enzyme cofactor activity, Leydig cell VDR-genomic signaling, and SHBG competition — producing additive rather than duplicative effects. Helian's technical approach translates this pathway-level understanding into a circadian-timed AM/PM protocol: steroidogenic activators delivered at the 07:00–09:00 testosterone peak window, cortisol-clearing compounds administered PM to restore the pregnenolone substrate available for overnight testosterone synthesis. This is not empirical stacking — it is mechanism-first formulation, timed to the axis it targets.
Frequently Asked Questions
Why is free testosterone a better clinical marker than total testosterone for supplement response tracking?
Total testosterone reflects both SHBG-bound (inactive) and albumin-bound plus free (bioavailable) fractions. SHBG concentrations vary 3–4 fold across the male population and increase with age, creating systematic measurement error in total T as a proxy for androgen status. Supplements like tongkat ali and boron act primarily by reducing SHBG or competing for binding sites — their effect will appear blunted or absent on total T assays while producing meaningful increases in free T and FAI. Equilibrium dialysis or Vermeulen-calculated free T is required to capture the actual therapeutic signal.
What is the clinical significance of the StAR protein as a rate-limiting step, and can it be nutritionally upregulated?
StAR is the acute regulator of steroidogenesis — it determines how rapidly cholesterol enters the mitochondrial inner membrane for CYP11A1 processing. LH/cAMP signaling upregulates StAR expression within 15–30 minutes; in the absence of LH pulsatility (as in chronic stress suppression of GnRH), StAR expression falls and testosterone output drops despite adequate enzymatic machinery. Vitamin D3/VDR signaling and eurycomanone have both been shown to upregulate StAR transcription in Leydig cell models, suggesting a nutritional lever at the rate-limiting step — though this has been demonstrated primarily in vitro and in rodent models.
Does the tongkat ali meta-analysis (PMID 36013514) SMD of 1.35 hold across eugonadal populations?
No. The large effect size (SMD = 1.35) was driven by studies in confirmed hypogonadal men. In subgroup analyses, eugonadal men showed substantially smaller effects (SMD approximately 0.4–0.6), and some studies in eugonadal populations did not reach statistical significance. The I² of 78% reflects this population heterogeneity. Clinically, this means tongkat ali is most appropriate for men with measurable HPG axis underactivity — low-normal testosterone, elevated LH attempting compensation, or frank hypogonadism. In a eugonadal male athlete, the SHBG-reduction effect may still be meaningful for free T optimization even when total T effects are modest.
What is the mechanistic basis for timing testosterone-support supplements to the morning window?
Testosterone biosynthesis is highest during the nocturnal/early morning hours, with peak circulating levels at 07:00–09:00. GnRH pulsatility from the suprachiasmatic nucleus drives nocturnal LH secretion, initiating Leydig cell steroidogenesis. Taking LH-amplifying compounds (tongkat ali) and steroidogenic cofactors (vitamin D3, zinc) at 07:00 aligns with the active phase of the axis — providing substrate and signaling amplification when the axis is already maximally engaged. PM administration of cortisol-modulating compounds (ashwagandha, magnesium) targets the competing pathway: reducing overnight cortisol load preserves pregnenolone substrate for the next morning's synthesis cycle.
Build your Low Testosterone protocol.
Helian builds a circadian-timed supplement protocol for your exact hormonal profile — AM and PM windows, evidence-based dosages.
See your Low Testosterone profile →